Physician profile
Hannah Harrison
NPI 1659996965
$574.19
in general payments reported to CMS, 2019-2025
12 companies · $574 in 2025
The $574 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.48 | 2025 | Hyqvia |
| Ucb, INC. | $69.49 | 2025 | Rystiggo |
| Lundbeck LLC | $61.61 | 2025 | Rexulti |
| Neurelis, INC. | $57.97 | 2025 | Valtoco |
| Averitas Pharma INC. | $57.07 | 2025 | Qutenza |
| Genentech USA, INC. | $53.87 | 2025 | Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $50.41 | 2025 | Symbravo |
| Abbvie INC. | $47.76 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.63 | 2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $24.50 | 2025 | Inbrija, Xeomin |
| Ipsen Biopharmaceuticals, INC | $22.06 | 2025 | Dysport |
| Amneal Pharmaceuticals LLC | $21.34 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.